A global research consultation convened by the WHO R&D plan brought together more than 500 experts and more than 2,000 participants to discuss the knowledge gaps and research priorities for monkeypox, in view of the recent outbreaks of the disease in both endemic and non-endemic countries.
High-level researchers and experts from around the world met virtually for 2 days to review the available evidence on the epidemiology of the virus; its transmission dynamics; clinical features; One Health Research; community participation; and countermeasures to manage the disease, including clinical care, treatments, and vaccines. They agreed that effective countermeasures should be in place depending on where the need was greatest.
Improving control of monkeypox in endemic countries is critical to addressing the increasing incidence of the disease and to controlling imports and outbreaks elsewhere. Participants agreed that enhanced collaboration between researchers from endemic countries, who have extensive experience and data on the disease, together with researchers from other countries, will ensure that scientific knowledge advances more rapidly.
Experts stressed the need for accelerated studies to better understand the epidemiology of the disease, its clinical consequences, and the role of different modes of transmission. In addition, the following research needs were highlighted: a comprehensive One Health approach to understanding animal-to-human transmission and animal reservoirs; development and evaluation of the best diagnostic tools that may be available worldwide; improved approaches to communicating and involving communities in affected areas; studies to optimize supportive clinical care; documentation of best control and treatment practices; and fast and transparent communication of data and scientific evidence.
Experts also stressed the need for clinical trials of vaccines and therapeutics to better document their effectiveness and understand how to use them in this and future outbreaks.
Prompt implementation of public health activities, such as the communication of prevention information, improved disease surveillance, contact monitoring, case isolation, and optimized care for people with the virus , should be used to limit the spread and help affected people, wherever they are. .
This consultation is part of a series of WHO activities in response to this outbreak in several countries.
About the R&D plan
The R&D Blueprint is a comprehensive strategy and preparedness plan that allows for the rapid activation of R&D activities during epidemics. Its aim is to accelerate the availability of effective tests, vaccines and medicines that can be used to save lives and prevent large-scale crises.
For each of these diseases, R&D roadmaps and, where appropriate, target product profiles (TPPs) and generic protocols are developed through extensive and open consultations with key experts and other stakeholders. In addition, efforts are being made to strengthen national regulatory and ethical bodies to respond to public health emergencies.